Transplantation for amyloidosis.
OBJECTIVE
High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature.


RESULTS
We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial.


CONCLUSIONS
Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.
Gertz
Morie A
MA
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertz.morie@mayo.edu
Lacy
Martha Q
MQ
Dispenzieri
Angela
A
Hayman
Suzanne R
SR
Kumar
Shaji
S
D000686:Amyloidosis / Q000145:classification / Q000401:mortality / Q000628:therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy; D011379:Prognosis; D033581:Stem Cell Transplantation; D016019:Survival Analysis
D000970:Antineoplastic Agents